Kinase modulation, and indications therefor

Patent metadata

Field	Value
Publication number	US-10123998-B2
Application number	US-201715669353-A
Country	US
Kind code	B2
Filing date	Aug 4, 2017
Priority date	Mar 19, 2012
Publication date	Nov 13, 2018
Grant date	Nov 13, 2018

Abstract

The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.

First claim

What is claimed is:

1. A method of treating a c-fms or c-kit mediated disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, wherein said disease or condition is neurofibromatosis-1 (NF1), cutaneous neurofibromas or plexiform neurofibromas.

2. The method of claim 1 , wherein the disease or condition is neurofibromatosis-1.

3. The method of claim 1 , wherein the disease or condition is cutaneous neurofibromas.

4. The method of claim 1 , wherein the disease or condition is plexiform neurofibromas.

5. The method of claim 1 , wherein the compound is administered orally.

6. The method of claim 5 , wherein the compound is administered in the form of a tablet.

7. The method of claim 5 , wherein the compound is administered in the form of a capsule.

8. The method of claim 1 , further comprising administering a Mek inhibitor to the subject, wherein the Mek inhibitor is administered simultaneously or sequentially with the compound.

9. The method of claim 8 , wherein the Mek inhibitor is administered simultaneously with the compound.

10. The method of claim 8 , wherein the Mek inhibitor is administered sequentially with the compound.

11. The method of claim 8 , wherein the Mek inhibitor is selumetinib.

12. The method of claim 1 , wherein the compound is administered at a dose ranging from about 0.01 to 50 mg/kg of the subject being treated.

13. The method of claim 1 , wherein the compound is administered at a dose ranging from about 0.1 mg/kg to 20 mg/kg of the subject being treated.

Assignees

• Plexxikon Inc

Inventors

• Bollag Gideon
• Hirth Klaus-Peter
• Ibrahim Prabha N
• Lin Paul
• West Brian

Classifications

• A61P25/30

  for treating abuse or dependence · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title